Age-Related Macular Degeneration – Market Trends and Forecasts: Technavio

LONDON--()--Technavio’s latest report on the global age-related macular degeneration (AMD) market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

Sapna Jha, a lead analyst from Technavio, specializing in research on cardiovascular and metabolic disorders sector, says, “AMD is an eye defect that affects the tiny part of the retina at the back of the eye called the macula. There are two types of AMD, namely dry and wet, which affects mostly people over 60 years of age and, if AMD is left untreated, it can lead to permanent vision loss.”

Special regulatory and fast track drug designations will act as a major boost to the AMD market during the forecast period. Such incentives have two-pronged benefits to the underlying vendors. First, they can launch their drugs into the market through quicker channels, and second, they get the tax benefits released by the respective governments under such schemes. For example, Ophthotech’s Fovista received fast-track designation from the US FDA and is expected to launch by 2018. Once launched, it is expected to get a high market share and will give strong competition to currently marketed drugs.

Request a sample report:

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

The top three emerging trends driving the global AMD market according to Technavio healthcare and life sciences research analysts are:

  • Novel treatment approaches for developing AMD drugs
  • Increased research grants, initiatives, and programs
  • Use of combination therapies

Novel treatment approaches for developing AMD drugs

The global AMD market is witnessing better treatment options for macular degeneration, which are expected to display promising results in the future. New research into the effects of the tissue inhibitor of metalloproteinase-3 (TIMP-3) could lead to the development of novel medicines to treat AMD. Also, two research groups with RNAi projects are looking into the possibility of silencing the genes for VEGF in AMD. Once confirmed, this new approach will open up for research in new medicines.

Similarly, ongoing research on mice proven better, more lasting treatment for macular degeneration, which uses a class of drugs known as murine double minute 2 inhibitors to degenerate the abnormal blood vessels responsible for the vision loss associated with AMD. The advantage that MDM2 inhibitors have over anti-VEGF is that they aim the leaky blood vessels straight away, whereas anti-VEGF targets the growth factors that lead to abnormal blood vessels,” according to Sapna.

Increased research grants, initiatives, and programs

Due to increase in the R&D activities in the treatment of AMD, various foundations offer grants to a researcher working in basic research in the understanding of AMD and also to the researcher working in translational AMD research focusing on therapeutics. For instance, the Macular Degeneration Foundation provides financial support to researchers investigating the treatment and helping those coping with the challenges associated with AMD.

The overall public awareness of the problems related to visual impairment has increased over the last decade because of the rise in the number of initiatives taken by governments and various organizations. The WHO, along with The International Agency for the Prevention of Blindness (IAPB), initiated the Vision 2020: The Right to Sight program in 2007.

Use of combination therapies

The AMD market is experiencing a shift toward combination products, using two or more effective treatments. Parallel with the introduction of novel, potent monotherapies for AMD, the market is facing a clear trend toward individualized medicine. The shortcomings of treatment with a single drug can overcome with the use of combination therapy. With AMD, this may mean combination therapy. The need for practical combination therapy exists to address these shortcomings of monotherapy. The goal of combination therapy is to disrupt the multiple stimuli that lead to pathologic cellular proliferation.

The key vendors are as follows:

  • Bayer HealthCare
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals

Browse Related Reports:

Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact with your requirements and our analysts will be happy to create a customized report just for you.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770

Release Summary

Technavio’s latest report on the global age-related macular degeneration (AMD) market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020.



Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770